Journal of Nuclear Medicine Technology December 2025, jnmt.125.270843; DOI: https://doi.org/10.2967/jnmt.125.270843 ...
Journal of Nuclear Medicine Technology December 2025, jnmt.125.271145; DOI: https://doi.org/10.2967/jnmt.125.271145 ...
Journal of Nuclear Medicine Technology December 2025, jnmt.125.271119; DOI: https://doi.org/10.2967/jnmt.125.271119 ...
Journal of Nuclear Medicine Technology December 2025, jnmt.125.271143; DOI: https://doi.org/10.2967/jnmt.125.271143 ...
Journal of Nuclear Medicine Technology August 2025, jnmt.125.269873; DOI: https://doi.org/10.2967/jnmt.125.269873 ...
Journal of Nuclear Medicine Technology December 2025, jnmt.125.270227; DOI: https://doi.org/10.2967/jnmt.125.270227 ...
Our strength as an organization comes from our members. Membership is more than a card in your wallet—it is a declaration that you believe in the value of nuclear medicine technology and in the power ...
At the Society of Nuclear Medicine and Molecular Imaging Annual Meeting, held June 21–24, in New Orleans, Louisiana, Julie Bolin, MS, CNMT, FSNMMI-TS, presented the SNMMI-TS Presidential Distinguished ...
Radioligand therapy (RLT) is a recent term for long established nuclear medicine practices. Although radioiodine provides the historical foundations of theranostics, the prototype RLTs include ...
The widespread success of 177Lu-PSMA-617 for prostate cancer has generated unprecedented volume in theranostics. Prostate-specific membrane antigen–targeted theranostics is possibly the most complex ...
A 25-question online survey was developed at Oregon Health & Science University (OHSU) to capture clinical practices related to [177 Lu]Lu-DOTATATE and [177 Lu]Lu-PSMA-617 therapies. A team of 7 ...
Theranostics is changing how we approach treatment in nuclear medicine. Combining targeted imaging with radiopharmaceutical therapy allows us to personalize care in ways that were not previously ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results